title: Sustained suppression of hepatitis C virus by high doses of interferon and ribavirin in adult hemophilic patients.
abstract: BACKGROUND
  In a recent randomized controlled study, only a minority (15%) of adult hemophiliacs with chronic HCV achieved a sustained virologic response to treatment with interferon (IFN) and ribavirin given at standard doses.
  
  
  METHODS
  Whether the therapeutic response might be improved in these patients by increasing the doses of IFN was evaluated. Thirty-four previously untreated, adult hemophiliacs with chronic HCV but negative for HIV were investigated. There were 33 men and 1 woman, aged 21 to 60 years (mean, 36). Twenty-three patients (68%) had genotype 1, and median serum HCV-RNA was 473 x 10(3) IU per L (range, 3.6-2145). Patients were treated with IFN at 5 million units (MU) thrice weekly for 6 months, followed by 3 mol/L for 6 additional months in combination with daily oral doses of 1 or 1.2 g of ribavirin.
  
  
  RESULTS
  A total of 33 patients (97%) completed the study; one patient withdrew because of treatment-related symptoms. Treatment dosage had to be reduced in 20 patients (59%). By intention-to-treat analysis, 14 patients (41%) had a sustained virologic response, particularly those infected by HCV genotype 2 or 3 (70% vs. 29% with genotype 1 or 4, p < 0.05). Sustained response rates were similar in the 13 compliant patients and the 20 patients who had to reduce IFN and/or ribavirin doses (54% vs. 35%).
  
  
  CONCLUSIONS
  High-dose IFN therapy plus ribavirin provided high rates of sustained virologic responses in adult hemophiliacs with chronic HCV, even if side-effects led to dose reduction in half of these patients.
authors.affiliation: Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and the Division of Hepatology, IRCCS Maggiore Hospital, University of Milan, Milan, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Santagostino
authors.forename: F
authors.initials: F
authors.lastname: De Filippi
authors.forename: M G
authors.initials: MG
authors.lastname: Rumi
authors.forename: M
authors.initials: M
authors.lastname: Rivi
authors.forename: M
authors.initials: M
authors.lastname: Colombo
authors.forename: P M
authors.initials: PM
authors.lastname: Mannucci
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage*; D015331:Cohort Studies; D004359:Drug Therapy, Combination; D005260:Female; D006467:Hemophilia A / Q000150:complications / Q000821:virology*; D016174:Hepacivirus / Q000187:drug effects*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D007372:Interferons / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D012254:Ribavirin / Q000008:administration & dosage*
chemical_list: D000998:Antiviral Agents; D012254:Ribavirin; D007372:Interferons